根据人群特征确定肺癌中胃泌素释放肽前体（ProGRP）的临界值。

Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.

作者信息

Bubanović Gordana, Pavićević Radomir, Franjević Ana

机构信息

Cancer Genetics Laboratory, Primary Reference Laboratory for Clinical Application of Lung Tumour Markers, University Hospital for Pulmonary Diseases "Jordanovac", Zagreb, Croatia.

出版信息

Coll Antropol. 2008 Dec;32(4):1155-64.

PMID:19149223

Abstract

The standardisation process consisted of determining tumour marker levels in all relevant population groups which are connected with the biology of the marker in normal and tumourous cells. This makes clinical application possible. ProGRP serum levels were measured in 273 healthy subjects, 176 patients with benign diseases and tumours, 200 with small cell lung cancer (SCLC), 294 with non-small cell lung cancer (NSCLC), 21 with carcinoid tumour, 93 with undifferentiated lung cancer, 35 with mixed SCLC-NSCLC, and 189 with other malignancies. ProGRP levels in patients with SCLC and SCLC-NSCLC were significantly higher than in all the other groups (p = 5.4 x 10(-3)). Moreover, in SCLC patients ProGRP levels significantly correlate with the extent of the disease and the patients' smoking habit. The cut-off level of ProGRP for SCLC is 65.89 pg/mL in the Croatian population. It is based on 96.8% specificity in benign diseases which cause problems in differential diagnosis. The sensitivity of ProGRP was 85% at the time of SCLC diagnosis.

摘要

标准化过程包括测定所有相关人群组中的肿瘤标志物水平，这些人群组与正常细胞和肿瘤细胞中标志物的生物学特性相关。这使得临床应用成为可能。对273名健康受试者、176名患有良性疾病和肿瘤的患者、200名小细胞肺癌（SCLC）患者、294名非小细胞肺癌（NSCLC）患者、21名类癌肿瘤患者、93名未分化肺癌患者、35名SCLC-NSCLC混合型患者以及189名其他恶性肿瘤患者测定了ProGRP血清水平。SCLC和SCLC-NSCLC患者的ProGRP水平显著高于所有其他组（p = 5.4×10⁻³）。此外，在SCLC患者中，ProGRP水平与疾病程度和患者吸烟习惯显著相关。克罗地亚人群中SCLC的ProGRP临界值为65.89 pg/mL。它基于在鉴别诊断中引起问题的良性疾病中的96.8%特异性。SCLC诊断时ProGRP的敏感性为85%。